Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Aligos Therapeutics, Inc.

Market Cap 31.62M 27.25M 25.08M 23.53M 44.2M 2.99B 44.64M 297M 116M 1.46B 119M 116M 5.06B P/E Ratio 2026 *
-0.73x
P/E Ratio 2027 * -1.2x
Enterprise Value 8.34M 7.19M 6.61M 6.21M 11.66M 788M 11.77M 78.2M 30.55M 386M 31.29M 30.63M 1.34B EV / Sales 2026 *
0.38x
EV / Sales 2027 * -50.1x
Free-Float
78.05%
Yield 2026 *
-
Yield 2027 * -
05-28 Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target MT
05-27 Aligos Therapeutics, Inc. Presents Positive Data On Pevifoscorvir Sodium And Pipeline Programs At EASL Congress 2026 CI
05-07 Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-17 Xiamen Amoytop Biotech Signs License Deal for Hepatitis B Drug MT
04-16 Aligos Therapeutics, Inc. and Xiamen Amoytop Biotech Co., Ltd. Enter Exclusive License Agreement for Pevifoscorvir Sodium in Greater China CI
04-14 Aligos Therapeutics announces first interim analysis results from the phase 2 B-Supreme study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection and grant of FDA fast track designation RE
04-14 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation CI
03-05 Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-04 Aligos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
02-04 Aligos Therapeutics, Inc. Announces Management Changes CI
01-21 Aligos Therapeutics provides phase 2 B-SUPREME study progress updates RE
01-21 Aligos Therapeutics, Inc. Announces Resignation of Hardean Achneck as Executive Vice President, Chief Medical Officer CI
01-21 Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates CI
1 day-3.22%
1 week+3.02%
Current month-10.35%
1 month-10.51%
3 months-32.50%
6 months-57.42%
Current year-45.17%
1 week 4.91
Extreme 4.91
5.55
1 month 4.8
Extreme 4.8
6.11
Current year 4.8
Extreme 4.8
10.49
1 year 4.8
Extreme 4.8
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
719
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 2018-02-04
Director of Finance/CFO 60 2020-05-31
Chief Tech/Sci/R&D Officer 65 2018-04-30
Director TitleAgeSince
Director/Board Member 64 2018-07-31
Director/Board Member 74 2018-07-31
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap.
03-08Free

Chief Financial Officer

37,485 0.7002%
03-08Free

Chief Technology Officer

23,310 0.4354%
03-08Free

Controller/Auditor

9,450 0.1765%
Change 5-day change 1-year change 3-year change Capi.($)
-3.22%+3.02%-33.72%-81.42% 31.62M
+0.96%+1.16%-12.97%-12.33% 43.58B
+4.02%+7.79%+294.33%+536.67% 34.03B
-1.69%-2.89%+13.70%-17.71% 29.77B
+1.41%-0.96%-0.53%+33.41% 29.82B
+1.16%+9.79%+14.27%+22.28% 25.42B
+2.40%+8.49% - - 13.87B
+0.03%+2.10%+56.75%+111.91% 13.35B
-1.09%-2.31%+5.07%+5.00% 12.85B
+0.93%+0.57%+107.81%+77.40% 12.22B
Average +0.49%+1.99%+49.41%+75.02% 21.5B
Weighted average by Cap. +1.07%+1.86%+61.39%+105.74%

Financials

2026 *2027 *
Net sales 21.68M 18.68M 17.19M 16.13M 30.3M 2.05B 30.6M 203M 79.4M 1B 81.35M 79.62M 3.47B 5M 4.31M 3.97M 3.72M 6.99M 473M 7.06M 46.89M 18.32M 231M 18.76M 18.37M 801M
Net income -93.95M -80.98M -74.53M -69.92M -131M -8.88B -133M -881M -344M -4.35B -353M -345M -15.05B -124M -107M -98.53M -92.43M -174M -11.74B -175M -1.16B -455M -5.75B -466M -456M -19.89B
Net Debt -23.28M -20.07M -18.47M -17.33M -32.55M -2.2B -32.87M -218M -85.29M -1.08B -87.37M -85.52M -3.73B -282M -243M -224M -210M -394M -26.67B -398M -2.65B -1.03B -13.06B -1.06B -1.04B -45.19B
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
26-06-15 5.110 $ -3.22% 87,564
26-06-12 5.280 $ 0.00% 76,681
26-06-11 5.280 $ +2.33% 50,030
26-06-10 5.160 $ +0.39% 32,523
26-06-09 5.140 $ +3.63% 81,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.110USD
Average target price
56.29USD
Spread / Average Target
+1,001.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!